ERYTECH Pharma S.A.
NASDAQ: ERYP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gil Beyen
- Employees
- 49
- Headquarters
- Lyon, France
- IPO year
- 2016
- Market cap
- $47.4M
- Website
- https://www.erytech.com
Loading ERYP…
Loading profile data…Frequently asked questions about ERYP
What does ERYTECH Pharma S.A. (ERYP) do?
ERYTECH Pharma S.A. is a biopharmaceutical company specializing in the clinical development of red blood cell-based treatments for various cancers and orphan diseases. Its operations are based in France and the United States. The company's most advanced investigational therapy, eryaspase, is currently undergoing Phase 3 clinical trials for secon...
Where does ERYP trade?
ERYTECH Pharma S.A. (ERYP) trades on the NASDAQ Global Select.
What sector is ERYP in?
ERYTECH Pharma S.A. (ERYP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ERYTECH Pharma S.A.?
Gil Beyen is the chief executive officer of ERYTECH Pharma S.A. (ERYP).
Where is ERYTECH Pharma S.A. headquartered?
ERYTECH Pharma S.A. is headquartered in France.
Does ERYP pay a dividend?
ERYTECH Pharma S.A. (ERYP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ERYP go public?
ERYTECH Pharma S.A. (ERYP) completed its initial public offering in 2016.
Is ERYP an ADR?
Yes — ERYP is an American Depositary Receipt; its underlying shares trade on a non-US exchange. ERYTECH Pharma S.A. reporting and dividends follow the underlying issuer.